Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
All peptides

Enfuvirtide

Also known as: Fuzeon
FDA-Approved

Enfuvirtide is a 36-amino-acid peptide approved as part of combination antiretroviral therapy in treatment-experienced HIV patients.

Buy Enfuvirtide on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Enfuvirtide is a 36-amino-acid peptide approved as part of combination antiretroviral therapy in treatment-experienced HIV patients.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

Binds gp41 to block conformational changes required for HIV-1 fusion with CD4 cells.

Current Research

TORO-1/2 trials support efficacy in resistant HIV.
Research strength: Strong

Potential Medical Uses

  • HIV-1 infection (combination therapy)

Potential Benefits

  • Activity against multi-drug-resistant HIV

Known Side Effects

  • Injection-site reactions (nearly universal)
  • Pneumonia risk
  • Hypersensitivity

Contraindications

  • Hypersensitivity

Drug Interactions

  • Few systemic drug interactions

Administration Methods

  • Subcutaneous injection twice daily

Half-life

~3.8 hours

Reconstitution

Reconstitute with sterile water, gently swirl (do not shake).

Storage & Handling

Room temperature powder; refrigerate reconstituted; use within 24 hours.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.